Pro 2013-007 (Announcement of Jianfeng Group on Providing Counter-Guarantees to Corporate Bond Counter-Guarantors)
Release time:
2020-08-05
证券代码:600668 证券简称:尖峰集团 编号:临2013-007
浙江尖峰集团股份有限公司
关于向公司债券反担保人提供反担保的公告
本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏,并对其内容的真实性、准确性和完整性承担个别及连带责任。
重要内容提示:
l本次担保的被担保人(质押权人)名称:天津帝士力投资控股集团有限公司
l本次担保金额:公司拟发行的规模不超过6亿元公司债券的本金及利息
l本次担保是否有反担保:本次对外担保实质是为公司发行公司债进行反担保
l对外担保逾期的累计数量:无
一、担保情况概述
2013年1月22日,公司召开的2013年第一次临时股东大会已批准关于公司发行票面总额不超过6亿元、期限不超过7年的公司债的相关议案,并授权董事会根据市场情况确定本次公司债券是否采用担保及具体担保方式,授权董事会及其授权人士(董事长、董事会秘书)全权办理本次发行公司债券相关事项。详见本公司2013年1月5日披露的《第八届董事会第八次会议决议公告》、《关于发行公司债券方案的公告》和2013年1月23日披露的《2013年第一次临时股东大会决议公告》,上述公告分别披露在《上海证券报》、《中国证券报》和上海证券交易所网站(http://www.sse.com.cn)上。
2013年2月26日,浙江尖峰集团股份有限公司以通信方式召开了第八届第九次董事会,公司现有董事9名,全部出席了本次会议,关联董事蒋晓萌先生、杜自弘先生回避了部分议案的表决,符合《公司法》和《公司章程》的有关规定,所做决议合法有效。经审议与表决,董事会以7票同意、0票反对、0票弃权审议通过了《关于向公司债券反担保人提供反担保的议案》。
为增强本次公司债的偿债保障,降低发行利率,本公司确定由天津天士力集团有限公司(以下简称:天士力集团)为本次公司债提供全额无条件的不可撤销的连带责任保证担保;由天士力集团的大股东天津帝士力投资控股集团有限公司(以下简称:帝士力控股)为天士力集团在该担保责任范围内提供保证方式的反担保。
由本公司将所持有的天士力集团20.76%股权质押给本次公司债券反担保人帝士力控股,作为本公司向帝士力控股在其担保责任范围内提供的反担保。授权公司董事长签署与上述担保及反担保相关的所有法律文件。
本次股权质押的质权人帝士力控股与本公司不存在关联关系;因本公司董事蒋晓萌先生和杜自弘先生也同时担任天士力集团的董事,根据上海证券交易所《股票上市规则》的相关规定,天士力集团是本公司的关联方。
二、被担保人(质押权人)基本情况
1、被担保人(质押权人)名称:天津帝士力投资控股集团有限公司。
2、成立时间: 1998年11月12日。
3、住所:天津北辰科技园区。
4、法定代表人:闫希军。
5、注册资本:3500万元。
6、经营范围:技术开发、咨询、服务、转让生物技术及产品,以自有资金对保健食品、高科技行业进行投资。
7、与本公司关系:帝士力控股为本公司联营公司天士力集团的第一大股东,与本公司不存在关联关系。
8、财务情况:
按经审计的合并财务报表口径,截至2011年末,帝士力控股资产总额1,110,405.48万元,负债总额683,441.77万元,所有者权益合计(含少数股东权益)426,963.71万元。2011年度,实现营业收入978,075.32万元,净利润(含少数股东权益)31,842.31万元。
按未经审计的合并财务报表口径,截至2012年三季度末,帝士力控股资产总额1,135,037.33万元,负债总额663,027.71万元,所有者权益合计(含少数股东权益)472,009.62万元;2012年1-9月,实现营业收入730,728.46万元,净利润(含少数股东权益)56,912.14万元。
三、股权质押反担保的主要内容
(一)股权质押反担保内容
天士力集团为本公司拟发行的票面总额不超过6亿元、期限不超过7年的公司债提供全额无条件不可撤消的连带责任保证担保。由帝士力控股为天士力集团在该担保责任范围内提供保证方式的反担保。
本公司将所持有的天士力集团20.76%股权质押给帝士力控股,作为本公司向帝士力控股在其担保责任范围内提供的反担保。
(二)用于设定质押的反担保资产情况
公司本次用于反担保的质押资产是所持有的天士力集团20.76%股权,截止2011年末,该部分股权的投资成本为5,067.34万元。
1、天士力集团成立于2000年3月30日,注册地址:天津北辰科技园区,现有注册资本:23,784.38万元,其中:帝士力控股占61.68%、本公司占20.76%。经营范围:对外投资、控股;天然植物药种植及相关加工、分离;组织所属企业开展产品的生产、科研、销售、进出口经营业务;各类商品、物资的批发、零售;技术开发、咨询、服务、转让生物技术(不含药品生产与销售)及产品等。天士力集团是以大健康产业为主线,以制药业为中心,集生产、投资于一体的多元化集团企业。截止2012年9月末,天士力集团持有上市公司天士力制药集团股份有限公司47.27%的股权。
2、用于设定质押的反担保资产账面价值:截至2011年12月31日,反担保资产经审计的长期股权投资帐面价值35,239.73万元。截至2012年9月30日,反担保资产未经审计的长期股权投资帐面价值46,012.89万元。
3、用于设定质押的反担保资产在用于本次质押前不存在质押或者其他第三人权利、不涉及诉讼、仲裁事项,不存在查封、冻结等司法措施等情形以及妨碍权属转移的其他情况。
4、天士力集团2011年度财务报告经具从事证券、期货业务资格的天健会计师事务所(特殊普通合伙)审计,并出具标准无保留意见的审计报告。截至2011年12月31日,天士力集团经审计的合并口径资产总额1,041,815.88万元,负债总额634,383.72万元,归属于母公司所有者权益合计169,366.60万元。2011年度,实现主营业务收入927,977.29万元,利润总额86,209.96万元,归属于母公司所有者的净利润24,656.61万元。
截至2012年9月末,天士力集团未经审计的合并口径资产总额1,090,843.81万元,负债总额612,510.59万元,归属于母公司所有者权益合计221,974.93万元。2012年1-9月,实现主营业务收入694,726.89万元,利润总额104,716.12万元,归属于母公司所有者的净利润56,550.32万元。
四、董事会意见
1、股权质押反担保的必要性
由天士力集团为本次公司债券提供担保能切实增强公司债的偿债保障,有利于降低债券发行成本。帝士力控股向天士力集团提供保证方式的反担保,同时本公司对帝士力控股提供股权质押方式的反担保,是本次公司债券担保方案的组成部分,已经2013年第一次临时股东大会决议授权。上述反担保措施符合本公司及股东的整体利益。
2、股权质押反担保风险
由帝士力控股向天士力集团提供保证方式的反担保, 本公司向帝士力控股提供股权质押方式的反担保,实质是为本公司自身的融资进行担保。只要本公司能够按期偿还公司债券的本息,本次股权质押反担保的风险很小,不会影响公司经营。
五、累计对外担保数量及逾期担保的数量
截止本公告披露日,公司及其控股子公司已批准的对外担保总额为7,000.00万元,占公司2011年经审计的合并口径归属于母公司所有者权益合计的4.93%;公司对控股子公司已批准的担保总额为73,000.00万元,占公司2011年经审计的合并口径归属于母公司所有者权益合计的51.40%。
截止本公告披露日,公司及其控股子公司对外担保实际余额为7,000.00万元,占公司2011年经审计的合并口径归属于母公司所有者权益合计的4.93%;公司对控股子公司的担保实际余额为18,481.00万元,占公司2011年经审计的合并口径归属于母公司所有者权益合计的13.01%。
截止本公告披露日,本公司没有逾期担保。
特此公告
浙江尖峰集团股份有限公司董事会
二〇一三年二月二十六日
More information
2020
11-03
Jinhua Municipal Party Committee Secretary Chen Long: I wish your enterprise better and better
On the morning of October 16, Chen long, secretary of the Jinhua Municipal CPC Committee, and his entourage came to the construction site of Jianfeng Pharmaceutical's internationalization project to investigate and affirmed the good development status and clear future development ideas of Jianfeng Pharmaceutical. At the construction site, Jiang Xiaomeng, chairman of the group company and chairman of the pharmaceutical company, introduced the overall situation of the investment scale, factory layout, and production direction of the Jianfeng Pharmaceutical internationalization project to Chen Long and his entourage. Huang Jinlong, general manager of the pharmaceutical company, accompanied Chen Long and his entourage to visit the preparation workshop under construction. The construction site is neat, tidy and orderly, and the facilities and equipment are perfect and advanced, all have been unanimously affirmed by the leaders who came to investigate. When learning that the peak internationalization project has introduced international advanced equipment, built in accordance with European and American standards, and its products are oriented to the international market, Chen long said happily: "your goals are very clear and your thinking is very clear. I wish your enterprise better and better!" (this newspaper reporter)
2020
10-23
Liu Haiping, vice mayor of Pu'er City, said during the survey: "Peak is an enterprise with feelings"
On September 30, Liu Haiping, member of the standing Committee of the Pu'er Municipal CPC Committee and vice mayor of Pu'er City, Yunnan Province, and relevant responsible persons of Pu'er City and Simao District, visited the company for investigation and research, and communicated with the leaders of the group company on topics such as further strengthening cooperation between the two sides. "Yunnan Jianfeng has not only developed well in Pu'er these years, achieved good benefits and contributed considerable tax revenue, but also made great contributions to promoting the economic development of Pu'er and the stability of the southwest border region. It is our 'star enterprise' and 'baby enterprise '." Liu Haiping said so in the exchange. He said that Pu'er is an important window for the implementation of the "Belt and Road" concept. It has good conditions in natural resources, transportation, electricity, etc., and the peak is a "sentimental enterprise" and has a good foundation in the local area. Strengthen cooperation; various government departments will also earnestly "stand on the platform" and "do a good job as a shopkeeper" to serve enterprises. Chairman Jiang Xiaomeng and General Manager Yu Jianhong exchanged views with Liu Haiping and his party on the layout of peak industry and strengthening cooperation with Pu 'er. After that, accompanied by General Manager Yu Jianhong and Deputy General Manager Huang Jinlong, Liu Haiping and his party visited the Jinxi Factory of Jianfeng Pharmaceutical Factory. (this newspaper reporter)
2020
10-09
The first batch of Jianfeng Pharmaceuticals to enter Jinhua (Shanghai) Science and Technology Center
News from our newspaper On September 16, at the unveiling ceremony of the Yangtze River Delta G60 Jinhua (Shanghai) Science and Technology Innovation Center and Jinhua (Shanghai) Talent Building, Jiang Xiaomeng, chairman of the group company and chairman of the pharmaceutical company, took over from Chen Long, secretary of the Jinhua Municipal Party Committee. The golden key with big red flowers. Spike Pharmaceuticals became one of the first seven companies to enter the center. The Yangtze River Delta G60 Jinhua (Shanghai) Science and Technology Center and Jinhua (Shanghai) Talent Building are the first "Science and Technology and Talent Enclave" in Shanghai in the nine cities of the Yangtze River Delta G60 Science and Technology Corridor, and the first cross-regional industrial collaborative innovation center in the Science and Technology Corridor. The center is located in Shanghai Lingang Songjiang Science and Technology City, with a total area of nearly 10,000 square meters. It includes two parts: science and technology innovation and talent service. There are five major centers, including talent service center, science and technology innovation exhibition center, business incubation center, enterprise research and development center, and talent project roadshow center. It is a science and technology innovation platform that integrates the functions of project incubation, recruitment of institutions, and talent recruitment. Chen Long, secretary of the Jinhua Municipal Party Committee, said in his speech at the unveiling ceremony that in the future, all scientific and technological enterprises stationed in Jinhua (Shanghai) Science and Technology Center and Talent Building can equally enjoy Jinhua's local science and technology and talent policies, so as to further break the space limitation, enable talents from the two places to share the most favorable treatment and convenient services, help enterprises to develop in Shanghai and achieve industrialization in Jinhua. At the ceremony, leaders such as Chen Long, secretary of the Jinhua Municipal Party Committee, and Cheng Xiangmin, secretary of the Shanghai Songjiang District Party Committee, awarded seven companies, including Jianfeng Pharmaceutical, the golden key to symbolize their entry. At the Yangtze River Delta Integrated Talent Cooperation Project Symposium held after the ceremony, Jiang Xiaomeng spoke as a representative of Jinhua entrepreneurs. He believed that Shanghai, as an international metropolis, has an agglomeration effect on high-end intellectual resources and grasps the first-class element resources of scientific and technological innovation in China and even the world. The establishment of G60 Jinhua (Shanghai) science and technology innovation center and talent building in the Yangtze River Delta helps Jinhua enterprises to take off in scientific and technological innovation and information exchange, which will provide strong and continuous scientific and technological support and intellectual support for the long-term development of enterprises in the future, and attract more excellent domestic and foreign talents to serve Jinhua enterprises, It plays a key role in further improving scientific research ability, innovation ability and personnel training. During the event, Jiang Xiaomeng successively accepted on-site interviews with "People's Daily", "Liberation Daily", "Zhejiang Daily" and other media. He said that the establishment of science and technology innovation and talent bases in Shanghai has greatly enhanced Jinhua's attractiveness to enterprises. "With this base, we don't need to introduce talents to Jinhua, but directly recruit talents in Shanghai, and at the same time enjoy Jinhua's various talent recruitment policies, and change Shanghai talents to Jinhua's use. This is a kind of bold. The innovation has greatly solved the dilemma of attracting talents for enterprises." As a settled enterprise, it will also make full use of its own advantages to continuously inject resource vitality into the science and technology innovation center, and continue to contribute to the long-term development of Jinhua's economy. (this newspaper reporter)
2020
09-22
Spike Pharmaceutical Added New Products
On September 3, Spike Pharmaceutical Company received the approval of the State Drug Administration for the registration of esomeprazole sodium for injection (approval number: 2020S00572). Esomeprazole sodium for injection is mainly used to treat low-risk patients with gastroesophageal reflux disease and acute gastric or duodenal ulcer bleeding when oral therapy is not applicable. It has been listed in the National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug List (2017 Edition) ", classified as Class B. According to industry statistics, 30 companies including Zhengda Tianqing and Qilu Pharmaceutical have been approved for listing in China. In 2019, domestic sales (including urban and county-level public hospitals, community and township health centers) were about 3.317 billion yuan. Jianfeng Pharmaceutical submitted an application for registration of esomeprazole sodium for injection to the State Food and Drug Administration in November 2013 and was accepted. Up to now, Jianfeng Pharmaceutical has invested nearly 15 million yuan in research and development for the project and has a corresponding production line. This time to obtain the injection of esomeprazole sodium drug registration approval, marking the peak pharmaceutical has the drug production, sales qualification, will further enrich the peak pharmaceutical product line, help to enhance the competitiveness of the peak pharmaceutical business. (Lu Yating, Liu Yang)
2020
09-11